Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 2292-2302, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Everhart, E. T.
Right arrow Articles by Jones, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Everhart, E. T.
Right arrow Articles by Jones, R. T.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 1997;43:2292-2302.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine

E. Thomas Everharta, Polly Cheung, Peter Shwonek, Karen Zabel, Eileen C. Tisdale, Peyton Jacob, III, John Mendelson and Reese T. Jones

Drug Dependence Research Center, Department of Psychiatry, University of California, San Francisco, San Francisco, CA 94143.
a Address correspondence to this author at: Langley Porter Psychiatric Institute, Box CPR–0984, University of California, San Francisco, 401 Parnassus Ave., San Francisco, CA 94143-0984. Fax 415-476-7690.

We describe a sensitive and specific method for the measurement of buprenorphine in human plasma. The method involves a structural analog as an internal calibrator, careful control of pH during sample extraction to maximize drug recovery, and back-extraction into acid followed by reextraction to eliminate endogenous interferences. After evaporation, sample residues are derivatized with heptafluorobutyric anhydride and analyzed by separation on a fused-silica polymethylsiloxane capillary column and electron-capture detection. Calibration curves were linear in the ranges 0.1–2.0 µg/L and 2.0–20 µg/L, with within-run CVs of 9.7% at 0.1 µg/L to 5.0% at 20 µg/L, and total CVs of 15.9% at 0.1 µg/L to 6.5% at 10 µg/L. The limit of quantification was 0.1 µg/L. The method was utilized in studies to determine the absolute bioavailability of sublingual doses of 2 mg of buprenorphine in 1 mL of 300 mL/L ethanol and the bioequivalence of sublingual 8-mg tablet and 300 mL/L ethanol solution formulations.




The following articles in journals at HighWire Press have cited this article:


Home page
 J Clin PharmacolHome page
D. A. Ciraulo, R. J. Hitzemann, E. Somoza, C. M. Knapp, J. Rotrosen, O. Sarid-Segal, A. M. Ciraulo, D. J. Greenblatt, and C. N. Chiang
Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials
J. Clin. Pharmacol., February 1, 2006; 46(2): 179 - 192.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.